Marker Therapeutics Inc. Common Stock (MRKR)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-and-Buffett investor, I start with business quality and staying power. Marker is a clinical-stage immuno-oncology firm with five employees and Phase 1 MT-601; it is not yet commercial. In fiscal 2024, the year ended 2024-12-31, revenue was $6.6M and net loss $10.7M, or EPS -$1.19. In fiscal 2025, the year ended 2025-12-31, revenue was $3.5M and net loss $12.2M, or EPS -$0.79. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was n/a and net loss $1.8M, or EPS -$0.09. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $751,691 and net loss $3.2M, or EPS -$0.16. That is not a compounding earnings stream; it is cash consumption. TTM FCF was -$9.8M, a FairStock FCF yield of -64.3% on the $15.2M market cap at the 2026-10-26 close. At that close, FairStock shows P/B 1.25, P/E -2.17, ROE -76.87%, ROCE -40.47%, Piotroski 3/9, and Altman Z -38.52—fragility, not margin of safety. A moat is not discernible; value rests on clinical data and financing. The $0.91 price is near the 52-week low of $0.84 and far below $2.46, but book cheapness is thin and losses make conventional valuation useless. I would need clinical validation, controlled cash burn, and financing runway before calling this investment-grade.

In plain English: Marker Therapeutics is a tiny clinical-stage biotech with five employees testing T-cell cancer therapies; it has no steady product revenue and has lost money in each of the last four years. The financial picture is weak: it is burning cash and its reported profits and returns are deeply negative. At $0.91 a share and a $15.2 million market value, the price looks speculative rather than clearly cheap, because the company still depends on trial success and outside financing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer